InfuSystem Hlds

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Integrated Therapy Services and Durable Medical Equipment segments. The Integrated Therapy Services segment focuses on providing electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics. The Durable Medical Equipment segment is involved in the rental, sale or leasing of pole-mounted and ambulatory infusion pumps to oncology practices, hospitals, and other clinical settings. The company was founded in August 2005 and headquartered in Rochester Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InfuSystem reports revenue growth but faces supply chain challenges

InfuSystem's Q4 2022 performance showed revenue growth but a decrease in adjusted EBITDA, with a focus on strategic partnerships and conservative guidance for 2023.
The company faces challenges with supply chain issues, reporting delays, and internal control deficiencies, but is actively addressing these issues.
Opportunities lie in expanding the supplier base, enhancing product offerings, and expecting gradual revenue growth in 2023, supported by key partnerships and growth initiatives.

InfuSystem reports record Q1 revenue, expands partnerships for growth

InfuSystem's Q1 2023 performance reflects strong revenue growth, successful partnerships, and strategic expansions, positioning the company for continued success in the healthcare services sector.
While facing challenges such as higher expenses and reimbursement complexities, InfuSystem's focus on innovation and financial stability underscores its resilience and growth potential.
By reaffirming annual guidance and emphasizing sustainable growth strategies, InfuSystem demonstrates a clear vision for driving profitability and market leadership in the coming quarters.

InfuSystem reports robust Q2 earnings, eyes growth in Wound Care

InfuSystem Holdings, Inc. delivered a strong performance in Q2 2023, driven by revenue growth and strategic business decisions. The company's financial results, progress in addressing internal control deficiencies, and raised guidance indicate a positive outlook for future growth. While challenges exist in scaling certain business segments, InfuSystem is well-positioned to capitalize on opportunities in Wound Care and the Sanara joint venture.

InfuSystem reports record Q3 revenue growth and strategic expansion plans

InfuSystem's Q3 2023 performance reflects robust revenue growth, improved profitability, and strategic initiatives for future expansion and operational efficiency.
While facing challenges such as margin pressures and market competition, the company's strengths in oncology and operational enhancements position it for long-term success.
Opportunities in revenue diversification, service expansion, and market presence offer InfuSystem avenues for sustained growth and profitability.
Overall, InfuSystem's strong financial results, strategic focus on growth drivers, and optimism for future performance paint a positive outlook for investors and stakeholders.

InfuSystem Hlds (INFU) reports record revenue in Q4 2023

InfuSystem Hlds (INFU) delivered a robust performance in Q4 2023, showcasing revenue growth and margin improvement. With a strategic focus on core business expansion and operational excellence, the company aims for steady growth in 2024 amidst industry challenges and regulatory changes.

InfuSystem reports strong Q1 revenue growth and strategic partnerships

InfuSystem's Q1 performance reflects revenue growth and profitability improvements driven by operational enhancements.
The company's strategic partnerships and focus on high-potential opportunities position it for sustained growth.
Challenges include market focus shifts and balancing expenses with revenue growth for long-term success.
Overall, InfuSystem's performance outlook remains positive, with confidence in achieving revenue and EBITDA targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Patient Services and Device Solutions segments. The Patient Services segment involves the durable medical equipment, clinic-to-home health care, logistics and billing, and oncology business. The Device Solutions segment includes the sale or rent of new and pre-owned pole-mounted and ambulatory infusion pumps, treatment-related consumables, biomedical recertification, maintenance and repair services for oncology practices. The company was founded by Steven E. Watkins in August 2005 and headquartered in Rochester Hills, MI.

Rochester Hills, Michigan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer will participate in Lake Street Capital Markets' 5th Annual Best Ideas Growth (BIG5) Conference on Tuesday, September 14, 2021, on a virtual platform.

InfuSystem to Participate in Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference September 14, 2021

Shares of INFU had been on a tear, ripping from $6/share after the “Covid crash,” to well over $22/share a year later.

InfuSystem: Looking Beyond The Headline Numbers

Sealed Air

Trean Insurance Group

Sealed Air, Trean Insurance Group and InfuSystems Holdings are trading close to or below their historical median valuations.

3 Stock Picks With Growth Potential

InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q2 2021 Results - Earnings Call Transcript

InfuSystems Holdings, Inc. (INFU) delivered earnings and revenue surprises of -63.64% and -9.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

InfuSystems Holdings, Inc. (INFU) Misses Q2 Earnings and Revenue Estimates

Launched Fourth ITS Therapy - Lymphedema Announced $20 million Stock Repurchase Program Updates Guidance for 2021

InfuSystem Reports Second Quarter 2021 Financial Results

Investor Conference Call to be held 9:00 a.m. Eastern Time Investor Conference Call to be held 9:00 a.m. Eastern Time

InfuSystem to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

InfuSystems Holdings, Inc. (INFU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in InfuSystems Holdings, Inc. (INFU): Can Its 14.2% Jump Turn into More Strength?

Providing pneumatic compression devices for last-mile patient care Providing pneumatic compression devices for last-mile patient care

InfuSystem Enters Lymphedema Therapy Market

ROCHESTER HILLS, Michigan, May 27, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Rich DiIorio, Chief Executive Officer, and Barry Steele, Chief Financial Officer, will participate at Craig-Hallum's 18th Annual Institutional Investor Conference on Wednesday, June 2, 2021, on a virtual platform.

InfuSystem to Participate at Craig-Hallum 18th Annual Institutional Investor Conference June 2, 2021

InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q1 2021 Results - Earnings Call Transcript

Net Revenues: $24.5 million, a 14% increase  Net Income: $0.7 million, a $1.1 million increase,  Adjusted EBITDA: $6.2 million, a 51% increase, and  Adjusted EBITDA margin of 25.2%, a 6.3% increase  Company Reaffirms Full Year 2021 Guidance

InfuSystem Reports First Quarter 2021 Financial Results

InfuSystem to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

ROCHESTER HILLS, Michigan, April 21, 2021 (GLOBE NEWSWIRE) --  InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that it has acquired the operating assets of OB Healthcare Corporation, a privately held, Texas-based, biomedical services company. Terms of the transaction were not disclosed.

InfuSystem Acquires OB Healthcare Corporation, Expanding DME Services Platform in Acute Care

INFU has more than tripled from the pandemic crash lows, but plenty of upside remains.

InfuSystem's Continued Execution Could Lead It To Double

Investor Presentation to be held 9:15 a.m. Eastern Time Investor Presentation to be held 9:15 a.m. Eastern Time

InfuSystem to Present at Sidoti's Spring 2021 Virtual Conference March 25, 2021

InfuSystem Holdings Inc.'s (INFU) CEO Rich Dilorio on Q4 2020 Results - Earnings Call Transcript

Full Year 2020 vs. Full Year 2019: Net Revenues: $97.4 million, a 20% increase Net Income: $17.3 million, a 15.9 million increase, Adjusted EBITDA: $26.2 million, a 44% increase, and Adjusted EBITDA margin of 27%, a 4.4% increase

InfuSystem Reports Fourth Quarter and Full Year 2020 Financial Results

InfuSystem to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 17, 2021

ROCHESTER HILLS, Michigan, March 02, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Carrie Lachance has been appointed as President in addition to her current role as Chief Operating Officer.

InfuSystem Announces Appointment of Carrie Lachance as President

RODCHESTER HILLS, Michigan, Feb. 11, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced it has secured a new $75 million revolving credit facility with JPMorgan Chase Bank, N.A., acting as the lead arranger with a syndicate of financial banking institutions that include Wells Fargo Bank, N.A., PNC Financial Services Group, Inc. and Comerica Bank.

InfuSystem Announces New $75 Million Revolving Credit Facility

Rochester Hills, Michigan, Feb. 03, 2021 (GLOBE NEWSWIRE) --  InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced it has acquired FilAMed, a privately held biomedical services company, based in Bakersfield, CA. Terms of the transaction were not disclosed.

InfuSystem Acquires Biomedical Services Company to Expand DME Services Platform

Euronav

360 Finance Inc - ADR

Growth-focused investors may be interested in the following small-cap stocks, as they represent companies whose trailing 12-month earnings per share improved significantly on a year-over-year basis.

A Trio of Small Caps for the Growth-Focused Investor

InfuSystem is uniquely positioned to benefit from any resurgence in COVID-19, and ex-COVID has strength in the core business model. Shareholders have enjoyed ~120% upside YTD, and shares have the legs to deliver more on the back of INFU's strong sequential performance YTD.

InfuSystem: Strength In Core Businesses Hedges Against COVID-19 Headwinds

Revenues of $107 million - $110 million; Adjusted EBITDA of $29 million - $30 million; Operating Cash Flow of $21 million - $23 million; Revenues of $107 million - $110 million; Adjusted EBITDA of $29 million - $30 million; Operating Cash Flow of $21 million - $23 million;

News for InfuSystem Hlds Stock (INFU)